Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...
IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...
Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...
PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 ...
Researchers from Washington University School of Medicine and Stanford University have developed a compound that simulates a ...
Pharmaceutical Technology on MSN15h
Allogeneic cell therapies “poised for prime time” says expertWhile the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...
Futurism on MSN18h
Students Concoct Ingenious Scheme To Grow Ozempic At HomeStudent scientists have developed an incredible new way to synthesize drugs on plants — and they're using Ozempic as their ...
Clinical Trials Arena on MSN23h
Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trialChinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...
Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times ...
Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...
In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...
Organelles in cells were originally often independent cells, which were incorporated by host cells and lost their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback